About Hereditary Cancer in Clinical Practice

What is Hereditary Cancer in Clinical Practice?

Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development of appropriate healthcare strategies.

Cancer genetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care.

Hereditary Cancer in Clinical Practice is an established journal published since 2003. This publication is partly financed by the Polish Ministry of Science and Higher Education.

The list of topics includes but is not limited to:

• Original research articles on any aspect of inherited predispositions to cancer
• Reviews of inherited cancer predispositions
• Application of molecular and cytogenetic analysis to clinical decision making
• Clinical aspects of the management of hereditary cancers
• Genetic counselling issues associated with cancer genetics
• The role of registries in improving health care of patients with an inherited predisposition to cancer

Content overview

Hereditary Cancer in Clinical Practice considers the following types of articles:

• Research: reports of data from original research.
• Reviews: comprehensive, authoritative, descriptions of any subject within the journal’s scope. These are usually written by opinion leaders invited by the Editorial Board.
• Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.
• Commentaries: short, focused and opinionated articles on any subject within the journal’s scope, which are usually related to a contemporary issue and may be commissioned from opinion leaders in the field.
• Debate articles: presentations of an argument that is not essentially based on practical research. Debate articles can report on all aspects of the subject including sociological, philosophical and ethical aspects.
• Letter to the Editor: these can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.

Peer review policy

Manuscripts are screened for general suitability before being assigned to at least two peer reviewers. Hereditary Cancer in Clinical Practice operates an 'open' peer-review system. Reviewers' names are included on the peer review reports, and reports are made publicly available. The Editors-in-Chief are responsible for the final decision on acceptance or rejection of a manuscript.

Edited by Jan Lubinski, Rodney J. Scott and Rolf Sijmons, Hereditary Cancer in Clinical Practice is supported by an expert Editorial Board.

Publishing in Hereditary Cancer in Clinical Practice

All articles are listed in PubMed immediately upon acceptance (after peer review), and are covered by PubMed Central, Thomson Reuters (ISI), CAS and Embase.

Articles in Hereditary Cancer in Clinical Practice should be cited in the same way as articles in a traditional journal. However, because articles in this journal are not printed, they do not have page numbers. Instead, they have a unique article number.

The following citation:

Hered Cancer Clin Pract 2004, 2:1

refers to article 1 from volume 2 of the journal.

As an online journal, Hereditary Cancer in Clinical Practice does not have issue numbers. Each volume corresponds to a calendar year.

To keep up to date with the latest articles from Hereditary Cancer in Clinical Practice, why not register to receive alerts? Registration also enables you to customise your subject areas of interest, store your searches, and submit your manuscripts.

Submission of manuscripts

Manuscripts should be submitted electronically to Hereditary Cancer in Clinical Practice using the online submission system. Full details of how to submit a manuscript are given in the instructions for authors.

General journal policies

Hereditary Cancer in Clinical Practice is published by BioMed Central, part of Springer Science+Business Media. BioMed Central is committed to ensuring peer-reviewed biomedical research is open access. That means it is freely and universally accessible online, it is archived in at least one internationally recognised free access repository, and its authors retain copyright, allowing anyone to reproduce or disseminate articles, according to the BioMed Central copyright and licence agreement. Hereditary Cancer in Clinical Practice however, has taken this further by making all its content open access.

Hereditary Cancer in Clinical Practice's articles are archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also at INIST in France and in e-Depot, the National Library of the Netherlands' digital archive of all electronic publications. The journal is also participating in the British Library's e-journals pilot project, and plans to deposit copies of all articles with the British Library.

BioMed Central is working closely with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Hereditary Cancer in Clinical Practice will be available.

Hereditary Cancer in Clinical Practice is able to deliver summaries of frequently updated content via Really Simple Syndication (RSS) feeds. These are accessible via the orange "XML" button at the top of the list of recent articles or the list of most accessed articles. For more information about RSS feeds see our publisher's website.

For further information about general policies please see the instructions for authors.